|
CEBPZ expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.88418203051333E-15 |
| Normal-vs-Stage2 |
1.01149977282944E-10 |
| Normal-vs-Stage3 |
6.55031584528842E-15 |
| Normal-vs-Stage4 |
5.55111512312578E-15 |
| Stage1-vs-Stage2 |
4.528200E-01 |
| Stage1-vs-Stage3 |
1.671850E-01 |
| Stage1-vs-Stage4 |
2.178000E-02 |
| Stage2-vs-Stage3 |
7.991200E-01 |
| Stage2-vs-Stage4 |
3.824600E-01 |
| Stage3-vs-Stage4 |
4.479000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
5.64880000000212E-05 |
| Normal-vs-Asian |
5.02289998483008E-09 |
| Caucasian-vs-AfricanAmerican |
1.745030E-01 |
| Caucasian-vs-Asian |
5.665800E-01 |
| AfricanAmerican-vs-Asian |
4.506800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.99200722162641E-16 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
3.536600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.77375908300337E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.63324909152607E-12 |
| Normal-vs-Age(81-100Yrs) |
2.619500E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.485240E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.911990E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.482200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.010000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.833800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.799200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.188300E-02 |
| Classical-VS-Follicular |
5.882300E-03 |
| Classical-VS-Other |
1.434620E-01 |
| Classical-VS-Normal |
1.63014046705712E-12 |
| Tall-VS-Follicular |
6.580800E-01 |
| Tall-VS-Other |
7.491400E-01 |
| Tall-VS-Normal |
4.29878355134861E-12 |
| Follicular-VS-Other |
6.519400E-01 |
| Follicular-VS-Normal |
1.75126579904372E-12 |
| Other-VS-Normal |
1.005200E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
1.24344978758018E-14 |
| N0-vs-N1 |
1.262050E-01 |
|
|
